Sinjard-M XR
Generic Name
Empagliflozin and Metformin Hydrochloride Extended-Release Tablet
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sinjard m xr 5 mg tablet | ৳ 30.00 | ৳ 210.00 |
Description
Overview of the medicine
Sinjard-M XR 5 mg Tablet is a combination medicine used to treat type 2 diabetes mellitus. It contains Empagliflozin and Metformin Hydrochloride (extended-release), which work together to improve blood sugar control.
Uses & Indications
Dosage
Adults
The usual starting dose is Empagliflozin 5 mg/Metformin HCl XR 1000 mg once daily, taken with the evening meal. Dosage should be individualized based on efficacy and tolerability, not exceeding maximum recommended doses of empagliflozin (25 mg) and metformin (2000 mg).
Elderly
No specific dose adjustment is required based on age, but renal function should be monitored due to increased risk of renal impairment in the elderly.
Renal_impairment
Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment or discontinuation may be necessary in moderate renal impairment, based on eGFR.
How to Take
Take the tablet orally once daily with the evening meal. Swallow the tablet whole; do not crush, cut, or chew it.
Mechanism of Action
Empagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, leading to increased urinary glucose excretion. Metformin reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
Pharmacokinetics
Onset
Within a few hours of administration.
Excretion
Empagliflozin is primarily excreted renally. Metformin is excreted renally as unchanged drug.
Half life
Empagliflozin: approximately 12 hours. Metformin: approximately 4-9 hours.
Absorption
Empagliflozin is rapidly absorbed. Metformin is slowly and incompletely absorbed from the gastrointestinal tract.
Metabolism
Empagliflozin undergoes glucuronidation. Metformin is not metabolized.
Side Effects
Contraindications
- •Hypersensitivity to empagliflozin or metformin or any component of the formulation
- •Diabetic ketoacidosis
- •Severe renal impairment (eGFR <30 mL/min/1.73m²)
- •Metabolic acidosis, including lactic acidosis
- •Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
Drug Interactions
Alcohol
Increases the risk of lactic acidosis with metformin.
Diuretics (e.g., Thiazide and Loop Diuretics)
May increase the risk of dehydration and hypotension when co-administered with empagliflozin.
Cationic drugs (e.g., Cimetidine, Trimethoprim, Ranitidine)
May reduce metformin excretion, leading to increased metformin plasma concentrations.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Overdose may lead to lactic acidosis (due to metformin). Symptomatic and supportive treatment is necessary. Hemodialysis may be considered in severe cases of lactic acidosis.
Pregnancy & Lactation
Not recommended during pregnancy (especially in the 2nd and 3rd trimesters) or breastfeeding. Consult a physician if considering use during these periods.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Available in pharmacies and hospitals nationwide
Approval Status
FDA/DGDA Approved
Patent Status
Patented (for Empagliflozin component and specific combination formulation)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in